Interpreting KEYNOTE-630 in the Context of C-POST

The faculty examine KEYNOTE-630, the adjuvant trial of pembrolizumab in cutaneous squamous cell carcinoma, and why it produced a different result than C-POST. Dr Whitman notes the two studies enrolled similar but not identical populations, with meaningful differences in eligibility and risk stratification that complicate direct comparison. Dr In offers his interpretation of what those differences may mean for practicing oncologists trying to reconcile the two datasets. The faculty are careful to separate trial design questions from drug-level conclusions, cautioning against inferring that one anti-PD-1 agent is inherently less active than another based on discordant trial outcomes. Both agree the KEYNOTE-630 result does not diminish confidence in the C-POST findings or in the adjuvant approval that followed. The segment offers practical context for clinicians encountering conflicting adjuvant immunotherapy data in cutaneous oncology and deciding how much weight to assign each study.